Spots Global Cancer Trial Database for sutent
Every month we try and update this database with for sutent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting | NCT00877045 | Gastrointestina... | 18 Years - | SCRI Development Innovations, LLC | ||
| Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent | NCT00836745 | Renal Cell Carc... | Non Interventio... | 18 Years - 75 Years | Pfizer | |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | NCT03035630 | Clear-cell Rena... RCC Kidney Cancer Clear-cell Kidn... | Avelumab Sunitinib | 18 Years - | Hoosier Cancer Research Network | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | NCT00434356 | Metastatic Brea... | bevacizumab sunitinib paclitaxel | 18 Years - | Genentech, Inc. | |
| Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma | NCT00509704 | Renal Cell Canc... | 18 Years - | Radboud University Medical Center | ||
| SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | NCT00577382 | Mucosal Lentigi... Acral Lentigino... | Sunitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | NCT00361244 | Colorectal Carc... | SU011248 Irinotecan Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma | NCT00393796 | Bladder Cancer | SUTENT Placebo | 18 Years - | University of Michigan Rogel Cancer Center | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing | NCT03109015 | Carcinoma, Rena... | Sunitinib Sunitinib | 18 Years - | Duke University | |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366 | Kidney Cancer | Everolimus Sunitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma | NCT00509704 | Renal Cell Canc... | 18 Years - | Radboud University Medical Center | ||
| Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | NCT01147822 | Carcinoma, Rena... | Pazopanib Sunitinib | 18 Years - | Novartis | |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer | NCT00631527 | Prostate Cancer | Leuprolide Goserelin Sunitinib Malat... Casodex Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma | NCT01108445 | Advanced Non-cl... | Everolimus Sunitinib | 18 Years - | Duke University | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | NCT00130897 | Carcinoma, Rena... | Sutent | 18 Years - | Pfizer | |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Study of SU11248 in Men With Advanced Prostate Cancer | NCT00299741 | Prostate Cancer | Sunitinib | 18 Years - | Massachusetts General Hospital | |
| SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | NCT00361244 | Colorectal Carc... | SU011248 Irinotecan Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT® | NCT00684645 | Metastatic Rena... | SUTENT | 18 Years - | Pfizer | |
| Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT00768144 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Sunitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | NCT00887575 | Breast Cancer | Paclitaxel Carboplatin Sunitinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma | NCT00788060 | Renal Cell Carc... | Everolimus (RAD... Sunitinib (Sute... | 18 Years - | Duke University | |
| A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | NCT00094029 | Gastrointestina... | Sutent | 18 Years - | Pfizer | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | NCT00887575 | Breast Cancer | Paclitaxel Carboplatin Sunitinib | 18 Years - | SCRI Development Innovations, LLC | |
| CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer | NCT02074878 | Breast Cancer | Crixotinib 200 ... Crixotinib 250 ... Crizotinib & Su... | 18 Years - | Baylor Breast Care Center | |
| A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | NCT00094029 | Gastrointestina... | Sutent | 18 Years - | Pfizer | |
| Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT00768144 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Sunitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | NCT01147822 | Carcinoma, Rena... | Pazopanib Sunitinib | 18 Years - | Novartis | |
| Ph I SU011248 + Irinotecan in Treatment of Pts w MG | NCT00611728 | Glioblastoma | SU011248 & Irin... | 18 Years - | Duke University | |
| A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) | NCT00434226 | Non-Small Cell ... | bevacizumab sunitinib carboplatin paclitaxel | 18 Years - | Genentech, Inc. | |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | NCT03035630 | Clear-cell Rena... RCC Kidney Cancer Clear-cell Kidn... | Avelumab Sunitinib | 18 Years - | Hoosier Cancer Research Network | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) | NCT01122615 | Renal Cell Canc... Kidney Cancer | Sunitinib Temsirolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Study of SU11248 in Men With Advanced Prostate Cancer | NCT00299741 | Prostate Cancer | Sunitinib | 18 Years - | Massachusetts General Hospital | |
| A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | NCT00094029 | Gastrointestina... | Sutent | 18 Years - | Pfizer | |
| Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma | NCT00393796 | Bladder Cancer | SUTENT Placebo | 18 Years - | University of Michigan Rogel Cancer Center | |
| Sunitinib Malate in Refractory Germ Cell Tumors | NCT00912912 | Genitourinary D... | Sunitinib Malat... | 18 Years - | M.D. Anderson Cancer Center | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | NCT00400569 | Liposarcoma Leiomyosarcoma Fibrosarcoma Malignant Fibro... | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
